查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1239518

骨發育不良市場：按類型、治療、分銷渠道分類：2021-2031 年全球機會分析和行業預測

Skeletal Dysplasia Market By Type, By Treatment, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 355 Pages | 商品交期: 2-3個工作天內

價格

2021年全球骨發育不良市場規模將達到16.381億美元，2022-2031年的複合年增長率為3.7%，預計2031年將達到23.6051億美元。

骨發育不良是一種罕見的疾病，有 450 多種類型。 它是一種影響軟骨和骨骼生長發育的疾病。 這種疾病的嚴重程度從中性致死到成年後無法茁壯成長不等。 骨發育不良的診斷很複雜，因為它是一種罕見的疾病。 主要症狀包括大頭畸形、生長遲緩、骨骼彎曲、上臂和大腿短小、關節痛和關節炎。

此病多見於兒童，早治早悟。 這種疾病是由基因缺陷引起的，這些缺陷在胎兒發育過程中發生突變或從父母雙方遺傳。 防禦基因是最難識別的。 因此，公司正在大力投資研發以尋找治療這種罕見疾病的方法。 由於患骨病的兒科人口增加、創新技術的引入、醫療保健支出增加、政府支持增加等，預計骨發育不良市場在預測期內將出現顯著的市場增長。 此外，公司增加研發投資、強大的管道候選人的存在以及醫療基礎設施開發支出的增加是推動市場增長的進一步因素。 然而，不斷上升的治療成本預計會阻礙市場增長。 另一方面，預計公共機構和私營公司的醫療保健投資激增將為骨發育不良市場提供重要的增長機會。

骨發育不良市場按類型、治療、分銷渠道和地區劃分。 按類型劃分，市場分為 Morquio A 綜合徵、X 連鎖低磷血症、低磷酸酯□症等。 通過治療，市場分為□替代療法、人單克隆抗體等。 按分銷渠道，市場分為醫院藥房、藥店和專業藥房以及在線供應商。

內容

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 主要投資領域
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 中等強度的競爭
  • 市場動態
    • 促進因素
      • 骨發育不良的患病率增加
      • 新藥的商業化和管道的存在
      • 增加政府在醫療保健方面的支出
      • 增加用於治療骨發育不良的臨床試驗和聯合調查
    • 抑制因素
      • 嚴格的法規和高昂的成本
    • 機會
      • 新興市場的增長機會
  • 分析 COVID-19 對市場的影響

第 4 章骨發育不良市場：按類型

  • 概覽
    • 市場規模和預測
  • Morquio A 症候群
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • X連鎖低磷血症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 低磷酸酯□症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章骨發育不良市場：按治療

  • 概覽
    • 市場規模和預測
  • □替代療法
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 人單克隆抗體
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章骨發育不良市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 藥店和專業藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章骨發育不良市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按治療分類的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 歐洲
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按治療分類的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按治療分類的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按治療分類的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 拉丁美洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 中東和非洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按治療分類的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測

第 8 章競爭格局

  • 介紹
  • 關鍵成功策略
  • 排名前 10 位的玩家產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 2021 年最佳球員排名

第 9 章公司簡介

  • Amgen Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Cipla Ltd
  • Biomarin Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck KGaA
  • Ascendis pharma a/s
  • Pfizer, Inc.
  • F. Hoffmann-La Roche AG
Product Code: A14433

The global skeletal dysplasia market size accounted for $1,638.10 million in 2021, and is expected to reach $2,360.51 million by 2031, registering a CAGR of 3.7% from 2022 to 2031.  

Skeletal dysplasia is a rare disease that has more than 450 types. The growth and development of cartilage and bone get affected by this disease. The level of severity of the disease varies from neutral lethality to growth different in adulthood. Skeletal dysplasia is complex to diagnosis, as it is rare disorder. Some of the major symptoms are deformities in the large head, slow growth, curved bones, short upper arms and thighs and joint pain or arthritis.  

This disorder is prevalent in children and early treatment can help to create awareness. This disorder is result of defective genes, which are either mutated during the development of fetus or inherited from parents. The defense gene is most complex to identify. As a result, businesses are investing significantly in research and development to find a cure for this rare condition. It is estimated that skeletal dysplasia market is expected to experience significant market growth during the forecast period owing to the increasing pediatric population suffering from bone disorder, the launch of innovative technologies, a boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure which further facilitate the growth of the market. However, High cost of treatment is expected to impede the market growth. In contrast, surge in healthcare investments in public as well as private sectors are anticipated to provide significant growth opportunities for the skeletal dysplasia market.    

The skeletal dysplasia market is segmented on the basis of type, treatment, distribution channel and region. On the basis of type, the market is bifurcated into morquio A syndrome, X-linked hypophosphatemia, hypophosphatasia and others. Depending on treatment, the market is classified into enzyme replacement therapy, human monoclonal antibody and others. By distribution channel, the market is classified into hospital pharmacies, drug stores and specialty pharmacies and online providers.  

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

The report provides a comprehensive analysis of the key players that operate in the global skeletal dysplasia market. The key companies profiled in the report include Amgen Inc., Ascendis Pharma a/s, AstraZeneca plc., Biomarin Pharmaceuticals Inc., Cipla Ltd, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck KGaA, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. 

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the skeletal dysplasia market analysis from 2021 to 2031 to identify the prevailing skeletal dysplasia market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the skeletal dysplasia market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global skeletal dysplasia market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Morquio A syndrome
  • X-linked hypophosphatemia
  • Hypophosphatasia
  • Others

By Treatment

  • Enzyme replacement therapy
  • Human monoclonal antibody
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Drug store and specialty pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players

  • Amgen Inc.
  • AstraZeneca plc
  • Cipla Ltd
  • Merck KGaA
  • Ascendis pharma a/s
  • F. Hoffmann-La Roche AG
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Biomarin Pharmaceuticals Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of skeletal dysplasia
      • 3.4.1.2. Commercialization of novel drugs and presence of pipeline products
      • 3.4.1.3. Increase in government expenditure on healthcare
      • 3.4.1.4. Increase in the number of clinical trials and collaborative research for skeletal dysplasia treatment
    • 3.4.2. Restraints
      • 3.4.2.1. Strict regulatory rules and high cost
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in the emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: SKELETAL DYSPLASIA MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Morquio A syndrome
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. X-linked hypophosphatemia
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Hypophosphatasia
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: SKELETAL DYSPLASIA MARKET, BY TREATMENT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Enzyme replacement therapy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Human monoclonal antibody
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug store and specialty pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: SKELETAL DYSPLASIA MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Treatment
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Treatment
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Treatment
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Treatment
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Treatment
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Treatment
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Treatment
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Treatment
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Treatment
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Treatment
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Treatment
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Treatment
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Treatment
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Treatment
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Treatment
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Rest of Asia-Pacific
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Treatment
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Treatment
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Treatment
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Treatment
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Amgen Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. AstraZeneca plc
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Eli Lilly and Company
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Cipla Ltd
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Biomarin Pharmaceuticals Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Teva Pharmaceutical Industries Ltd.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Merck KGaA
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Ascendis pharma a/s
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Pfizer, Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. F. Hoffmann-La Roche AG
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. SKELETAL DYSPLASIA MARKET FOR MORQUIO A SYNDROME, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. SKELETAL DYSPLASIA MARKET FOR X-LINKED HYPOPHOSPHATEMIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. SKELETAL DYSPLASIA MARKET FOR HYPOPHOSPHATASIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. SKELETAL DYSPLASIA MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. GLOBAL SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. SKELETAL DYSPLASIA MARKET FOR ENZYME REPLACEMENT THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. SKELETAL DYSPLASIA MARKET FOR HUMAN MONOCLONAL ANTIBODY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. SKELETAL DYSPLASIA MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. SKELETAL DYSPLASIA MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. SKELETAL DYSPLASIA MARKET FOR DRUG STORE AND SPECIALTY PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. SKELETAL DYSPLASIA MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. SKELETAL DYSPLASIA MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. NORTH AMERICA SKELETAL DYSPLASIA MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. U.S. SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. CANADA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. MEXICO SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. EUROPE SKELETAL DYSPLASIA MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. GERMANY SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. FRANCE SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. UK SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. ITALY SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. SPAIN SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. REST OF EUROPE SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. JAPAN SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. CHINA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. INDIA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. REST OF ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. REST OF ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. REST OF ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. LAMEA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. LAMEA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. LAMEA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. LAMEA SKELETAL DYSPLASIA MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. LATIN AMERICA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LATIN AMERICA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LATIN AMERICA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. MIDDLE EAST AND AFRICA SKELETAL DYSPLASIA MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. MIDDLE EAST AND AFRICA SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. MIDDLE EAST AND AFRICA SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. AMGEN INC.: KEY EXECUTIVES
  • TABLE 77. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 78. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 79. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 80. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 81. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 82. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 83. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 84. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 85. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 86. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 87. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 88. CIPLA LTD: KEY EXECUTIVES
  • TABLE 89. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 90. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 91. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 92. BIOMARIN PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 93. BIOMARIN PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 94. BIOMARIN PHARMACEUTICALS INC.: PRODUCT SEGMENTS
  • TABLE 95. BIOMARIN PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 96. BIOMARIN PHARMACEUTICALS INC.: KEY STRATERGIES
  • TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 101. MERCK KGAA: KEY EXECUTIVES
  • TABLE 102. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 103. MERCK KGAA: PRODUCT SEGMENTS
  • TABLE 104. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 105. ASCENDIS PHARMA A/S: KEY EXECUTIVES
  • TABLE 106. ASCENDIS PHARMA A/S: COMPANY SNAPSHOT
  • TABLE 107. ASCENDIS PHARMA A/S: PRODUCT SEGMENTS
  • TABLE 108. ASCENDIS PHARMA A/S: PRODUCT PORTFOLIO
  • TABLE 109. ASCENDIS PHARMA A/S: KEY STRATERGIES
  • TABLE 110. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 111. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 112. PFIZER, INC.: PRODUCT SEGMENTS
  • TABLE 113. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 114. PFIZER, INC.: KEY STRATERGIES
  • TABLE 115. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
  • TABLE 116. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 117. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
  • TABLE 118. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. SKELETAL DYSPLASIA MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF SKELETAL DYSPLASIA MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN SKELETAL DYSPLASIA MARKET (2022-2031)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALSKELETAL DYSPLASIA MARKET
  • FIGURE 10. SKELETAL DYSPLASIA MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR MORQUIO A SYNDROME, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR X-LINKED HYPOPHOSPHATEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR HYPOPHOSPHATASIA, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 15. SKELETAL DYSPLASIA MARKET, BY TREATMENT, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR ENZYME REPLACEMENT THERAPY, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR HUMAN MONOCLONAL ANTIBODY, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 19. SKELETAL DYSPLASIA MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR DRUG STORE AND SPECIALTY PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF SKELETAL DYSPLASIA MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 23. SKELETAL DYSPLASIA MARKET BY REGION, 2021
  • FIGURE 24. U.S. SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. CANADA SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. MEXICO SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. GERMANY SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. FRANCE SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. UK SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. ITALY SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. SPAIN SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. REST OF EUROPE SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. CHINA SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. LATIN AMERICA SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. MIDDLE EAST AND AFRICA SKELETAL DYSPLASIA MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43. COMPETITIVE DASHBOARD
  • FIGURE 44. COMPETITIVE HEATMAP: SKELETAL DYSPLASIA MARKET
  • FIGURE 45. TOP PLAYER POSITIONING, 2021
  • FIGURE 46. AMGEN INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 47. AMGEN INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 48. ASTRAZENECA PLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 49. ASTRAZENECA PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 50. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 51. ELI LILLY AND COMPANY: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 52. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 53. BIOMARIN PHARMACEUTICALS INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 55. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 56. MERCK KGAA: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 57. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 58. MERCK KGAA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 59. ASCENDIS PHARMA A/S: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 60. ASCENDIS PHARMA A/S: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. PFIZER, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. PFIZER, INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 64. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2021 (%)